Cargando…
Integrated analysis for treatment scheme of sodium–glucose cotransporter 2 inhibitors in patients with diabetic kidney disease: a real-world study
Sodium–glucose cotransporter 2 inhibitors (SGLT2i) are recommended for type 2 diabetes mellitus patients with impaired renal function, but the actual situation of SGLT2i using is unclear. Therefore, in this real-world study, we analyzed the treatment scheme and clinical characteristics of SGLT2i in...
Autores principales: | Fang, Li, Li, Guangpu, Ren, Jingjing, Duan, Jiayu, Dong, Jiancheng, Liu, Zhangsuo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10097684/ https://www.ncbi.nlm.nih.gov/pubmed/37045938 http://dx.doi.org/10.1038/s41598-023-33211-1 |
Ejemplares similares
-
Prediction and Risk Stratification of Cardiovascular Disease in Diabetic Kidney Disease Patients
por: Ren, Jingjing, et al.
Publicado: (2022) -
The Cardiovascular Benefits Associated with the Use of Sodium-Glucose Cotransporter 2 Inhibitors – Real-World Data
por: Gallwitz, Baptist
Publicado: (2018) -
Real-world evidence on sodium-glucose cotransporter-2 inhibitor use and risk of Fournier’s gangrene
por: Yang, Jeff Yufeng, et al.
Publicado: (2020) -
Challenges and opportunities in real‐world evidence on the renal effects of sodium‐glucose cotransporter‐2 inhibitors
por: Fadini, Gian Paolo, et al.
Publicado: (2021) -
Sodium-glucose cotransporter-2 inhibitor use in kidney transplant recipients
por: Ramakrishnan, Pavithra, et al.
Publicado: (2023)